TransMedics names new CFO and reiterates 2026 revenue guidance

TransMedics Group, Inc. (Nasdaq: TMDX) announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026. Araujo succeeds Gerardo Hernandez, who will move to a Commercial Strategic Advisor role focused on Latin America expansion.

Araujo brings more than 20 years of public-company finance experience. Most recently, he served as CFO of GE HealthCare's Advanced Imaging Solutions segment, a $16 billion business. He previously held the role of Corporate Finance CFO at GE HealthCare and served as Senior Vice President of Finance for Enterprise Operations at 3M. Earlier in his career, he spent 17 years at General Electric in various senior finance and CFO roles across healthcare and energy businesses.

"Fernando joins TransMedics at a growth inflection point," said Waleed Hassanein, M.D., President and CEO, citing plans to scale U.S. heart and lung operations, expand the product pipeline with OCS Kidney and OCS Gen-3.0, and build out international commercial and logistics operations across Europe.

Concurrent with the leadership announcement, TransMedics reiterated its full-year 2026 revenue guidance of $737 million to $757 million, representing approximately 22% to 25% year-over-year growth. The guidance excludes any revenue contribution from the company's recent strategic investment in PAD Aviation Service GmbH. The company said it expects to revisit the outlook alongside its third-quarter 2026 results.

TransMedics management is also scheduled to participate in fireside chats at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, and the Baird 2026 Global Healthcare Conference on September 15, 2026, both in New York.

You May Also Be Interested In

• RUM Group to raise Northern Data stake to ~98% via share purchase
• OPI prices $425M in senior secured notes due 2031
• Capital Southwest prices $350M notes offering at 6.75% due 2031